iOS app Android app

Robin L. Smith
Dr. Robin L. Smith served as Chairman and Chief Executive Officer of NeoStem from 2006 t0 2015 and was named Executive Chairman of NeoStem in 2015. Leveraging her expertise in medicine and business development, Dr. Smith has positioned NeoStem as a leader in the emerging stem cell industry, built on a successful business model that combines a proprietary therapeutic development business and a successful contract development and manufacturing organization (CDMO) which provides services to others in the regenerative medicine industry.

Under Dr. Smith’s leadership, NeoStem has successfully completed six acquisitions, one divestiture and has raised over 180 million dollars for research and development, expansion of business units, and strategic transactions. NeoStem ranked number 1 two years in a row in the Tri-State region and number 11 nationally on Deloitte’s 2013 Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. In 2010, NeoStem was awarded the New Economy “Best Stem Cell Company” award.

Dr. Smith was selected as a winner of the 2014 Brava! Award, an award celebrating the distinguished achievements of top women business leaders in the Greater New York area. She was also honored as a finalist for the 2014 EY Entrepreneur Of The Year award for the New York area, recognizing entrepreneurs who demonstrate excellence and success in the areas of innovation, financial performance and personal commitment to their businesses and communities.

Dr. Smith has an extensive and diversified background in health care, sales and marketing, business development and management. Her previous experience includes serving as President and Chief Executive Officer of IP2M, a multi-platform media company specializing in healthcare, where under her leadership, the company was selected as being one of the 10 fastest growing technology companies in Houston. She also previously held the position of Executive Vice President and Chief Medical Officer for HealthHelp, Inc., a National Radiology Management company that managed a large percentage of the healthcare dollars spent by large insurance companies. Dr. Smith has acted as a senior advisor to, and investor in, both publicly traded and privately held companies where she has played a significant role in restructuring and/or growing such businesses.

Dr. Smith has extensive experience serving in executive and board level capacities for various medical enterprises and healthcare-based entities. She currently serves on the Board of Directors of Signal Genetics (NASDAQ: SGNL), as well as on the Board of Trustees of the NYU Langone Medical Center. She is also past Chairman of the Board of Directors for the New York University Hospital for Joint Diseases. Currently, Dr. Smith is the President and Chairman of the Board of Directors of The Stem for Life Foundation, a non-profit entity that seeks to raise public awareness of adult stem cell therapies and their therapeutic applications. She also serves on the Board of Directors of the Science and Faith STOQ Foundation in Rome, as well as on the Capital Formation Committee of the Alliance for Regenerative Medicine.

Dr. Smith earned her M.D. from Yale University and her M.B.A. from the Wharton School of Business.

Entries by Robin L. Smith

The Longevity Paradox: Healthy Bodies, Fragile Minds

(0) Comments | Posted March 25, 2015 | 3:36 PM

Whether Methuselah or Dorian Gray, long lives and the idea of human immortality have always captured public imagination, inspiring countless works of art, religious dialogue and scientific innovation. And as I look across today's medical landscape, and see so many promising breakthroughs for chronic illnesses on the horizon -- such...

Read Post

Traumatic Brain Injuries, Stem Cells and Children: A Conversation With Dr. Charles Cox

(0) Comments | Posted February 13, 2015 | 4:37 PM

One of the world's leading experts on cellular therapies for traumatic brain injury (TBI), Dr. Cox directs the Pediatric Surgical Translational Laboratories and Pediatric Program in Regenerative Medicine at the University of Texas Medical School at Houston, as well as the Pediatric Trauma Program at the University of Texas-Houston/Children's Memorial...

Read Post

Cancer's Next Big Thing -- Immunotherapy

(5) Comments | Posted December 15, 2014 | 10:45 AM

The headlines have been coming all year from some of the biggest names in cancer drug discovery and development -- from Merck, Bristol-Myers Squibb and AstraZeneca. And just last month, data from Roche's advanced bladder cancer study lit up the international medical...

Read Post

The Regeneration Generation: A Conversation With Bob Hariri, Vice-Chairman and Co-Founder of Human Longevity Inc.

(0) Comments | Posted November 26, 2014 | 4:25 PM

Bob Hariri, M.D., Ph.D., is the vice chairman of Human Longevity Inc. (HLI), a genomics and cell-therapy diagnostics and therapeutics company he co-founded in 2013 with Craig Venter and Peter Diamandis, which is focused on extending the healthy, high-performance human lifespan. Utilizing technological advancements in genomics, bioinformatics, computing and cell...

Read Post

The Ice Bucket Halo

(0) Comments | Posted September 16, 2014 | 4:49 PM

As the founder of a healthcare charity, the Stem for Life Foundation, I am filled with awe and hope at the remarkable success of the Ice Bucket Challenge and Stand Up to Cancer. Taken together, these events have raised well over $200 million for...

Read Post

A Talk With C. Randal Mills, New Head of the California Institute for Regenerative Medicine

(0) Comments | Posted July 21, 2014 | 6:59 PM

In April 2014, C. Randal Mills was named President and CEO of CIRM, the California Institute for Regenerative Medicine, a San Francisco-based agency created in 2004 to allocate over $3 billion in funding for stem cell research for California. As the former CEO of Osiris Therapeutics Inc., the first company...

Read Post

President Obama and the Embryonic Backfire

(3) Comments | Posted November 7, 2012 | 9:34 AM

As Barack Obama begins his second administration, now is the time to examine the impact his re-election will have on stem cell research and the broader regenerative medicine industry. Before diving into those implications, however, it's important for us to understand how perceptions of stem cell science have changed in...

Read Post